A forensic guide to pharmaceutical life cycle extension: the IP strategies, regulatory mechanics, and commercial execution frameworks that separate drugs […]
Five Plays That Keep Your Blockbuster Drug Alive After the Patent Clock Runs Out Read Post »
Somewhere in the patent office’s public records, there is a graveyard. It has no physical address and no memorial plaques,
When Big Pharma Walks Away: What Abandoned Patents Reveal About Pipeline Priorities Read Post »
Pharmaceutical executives are losing control of their product narratives. While marketing teams focus on search engine optimization and field sales,
Stop AI Hallucinations From Destroying Your Drug Brand Value Read Post »
Pfizer’s finance team did not need a news alert to know Lipitor was in trouble. By 2010, the company’s own
Reliable pharmaceutical market forecasting requires moving beyond a simple reading of the FDA Orange Book. Investors and analysts frequently treat
A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model Read Post »
The pharmaceutical industry operates on a model where the expiration of a primary patent is no longer the end of
The Cliff Is Real, and the Numbers Are Getting Worse The pharmaceutical revenue cliff is not a metaphor. It is
The pharmaceutical industry spent roughly $2.3 billion and 12 years, on average, bringing a single new molecular entity to market
Get fresh news and insights, drug patent expirations & more…
